1 / 50

Cardiology Board Review

Cardiology Board Review. Brenda Shinar, MD February 26, 2013. Question 1. Answer: C. Exercise electrocardiography. www.afp.org/online/en/home/cme/selfstudy/cmebulletin/cardiac-testing/objectives January 2012. Understand the Tests Used for Coronary Artery Disease Diagnosis and Prognosis.

rock
Download Presentation

Cardiology Board Review

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Cardiology Board Review Brenda Shinar, MD February 26, 2013

  2. Question 1. • Answer: C. Exercise electrocardiography www.afp.org/online/en/home/cme/selfstudy/cmebulletin/cardiac-testing/objectives January 2012

  3. Understand the Tests Used for Coronary Artery Disease Diagnosis and Prognosis Indications to Order a Stress Test: Types of Stress: Exercise Dobutamine Vasodilator Types of Imaging with Stress: No imaging (EKG interpretation only) Nuclear Echocardiogram • To diagnose occlusive CAD in a symptomatic patient with intermediate pre-test probability for CAD • To prognosticate in a patient with known occlusive CAD • To screen for CAD in an asymptomatic high risk patient prior to high risk surgery

  4. Question 2. • Answer: C. Loop event recorder Ambulatory Arrhythmia Monitoring: Choosing the Right Device: Zimetbaum, Peter; Circulation 2010;122:1629-1636

  5. Understand the Tests Used to Identify Symptomatic Arrhythmias • Is there a rhythm disturbance that correlates with the patient’s symptoms? • How frequently do the symptoms occur? • Is the patient able to push a trigger with the symptom onset? • Holter 24 hour monitor • Continuous monitoring • Loop event recorder • Continuous monitoring, but only saved with patient trigger • Saves preceding several seconds of rhythm • Post-symptom event recorder • No preceding rhythm (may miss the arrhythmia)

  6. Question 3. • Answer: A. Current smoking

  7. Understand the 9 risk factors for CAD and their degree of importance according to INTERHEART study RISK FACTOR • Dyslipidemia • Tobacco smoking • Psychosocial Stress • Diabetes mellitus • Hypertension • Abdominal obesity • Moderate alcohol intake • Exercise • Vegetables/fruits daily • All risk factors ORAR (%) • 3.25 49.2 • 2.87 35.7 • 2.67 32.5 • 2.37 9.9 • 1.91 17.9 • 1.62 20.1 • 0.91 6.7 • 0.86 12.2 • 0.70 13.7 • 129.20 90.4

  8. Question 4. • Answer: B; Atorvastatin and epifibatide

  9. Initiate medical therapy in a high-risk patient with a non-ST elevation MI EARLY INVASIVE STRATEGY CONSERVATIVE STRATEGY Low Risk TIMI score (0-2) Physician or patient preference in absence of high risk features • Elevated biomarkers • New ST depression • High risk TIMI score (≥3) • Signs of heart failure • Hemodynamic instability • PCI within 6 months • Prior CABG • Continued angina despite aggressive medical therapy • Reduced LV function (EF <40%)

  10. Question 5. • Answer: C; Start metoprololsuccinate Chronic Heart Failure: Contemporary Diagnosis and Management; Gutam V. Ramani, et al: Mayo Clinic Proceedings; February 2010;85(2):180-195

  11. Know the appropriate treatment for systolic heart failure

  12. Question 6. • Answer: A; Candesartan

  13. Understand the significance of diastolic heart failure Definition: • Classic signs and symptoms of heart failure • Preserved LV EF • Invasive or imaging-based evidence of abnormal diastolic function Epidemiology: • 50% to 66% of patients with heart failure over 70 years of age Pathophysiology of Remodeling: • Near-normal end diastolic volumes • Increased wall thickness • Increased ratio of wall thickness to chamber diameter Management: • Treat blood pressure ARB (CHARM trial) decreased hospitalizations but not mortality • Rate/rhythm control in AF • Diuretics • Revascularize if indicated

  14. Question 7. • Answer: D; Placement of implantable cardioverter-defibrillator

  15. Know the risk factors for sudden death in patients with HOCM RISK FACTORS for SCD in HOCM • *Cardiac arrest • *Spontaneous sustained ventricular tachycardia • *Family history of sudden death age < 40 • Unexplained syncope • LV diastolic wall thickness > or = 30 mm • Blunted increase (< 20 mm Hg) or decrease in systolic BP with exercise • Nonsustained VT • Heart failure that has progressed to dilated cardiomyopathy * These patients should be given an AICD for prevention of sudden cardiac death This patient also needs a surgical myotomy procedure…

  16. Question 8. • Answer: D; Phenylephrine

  17. Diagnose and Manage a Patient with HOCM Dynamic outlet obstruction WORSENED by (murmur is louder): • Decreased preload • Lasix, nitroglycerin • Increased contractility • Digoxin, dobutamine • Decreased afterload • Sodium nitroprusside, ACEI, hydralazine, milrinone Medications that are helpful in HOCM: Fluids B-blockers Phenylephrine MANEUVERS: • Decrease preload: • Valsalva • Increase preload: • Squat • Increaseafterload: • Isometric hand grip

  18. Question 9. • Answer: A; Atrial tachycardia

  19. Diagnose an acute supraventricular tachycardia ATRIAL TISSUE ONLY • Multifocal atrial tachycardia • Variable P-wave morphology and variable PP and PR interval • COPD • Automatic Ectopic Atrial Tachycardia • Usually abrupt onset and termination • May be hard to distinguish from sinus tachycardia • Dig toxicity and hypokalemia • Atrial flutter • re-entry within the atrium • Atrial fibrillation • age, HTN, atrial enlargement, thyrotoxicosis AV JUNCTION INVOLVED • Paroxysmal Supraventricular Tachycardia • Re-entry within the AV node • TERMINATES 95% of the time with appropriate use of adenosine • Junctional Tachycardia • Increased automaticity within the lower part of the AV node (N-H region) • Dig toxicity and severe CHF • May terminate with adenosine

  20. Question 10. • Answer: C; Cardioversion

  21. Patients with atrial fibrillation who are hemodynamically unstable should undergo immediate cardioversion

  22. Question 11. • Answer: E; No bridging agent is needed Perioperative Management of Warfarin and Antiplatelet Therapy; Amir K. Jaffer; Cleveland Clinic Journal of Medicine; 2009 (76 Supplement 4) S37-44

  23. Question 12. • Answer: A; Postpone surgery for 6 months Perioperative Management of Warfarin and Antiplatelet Therapy; Amir K. Jaffer; Cleveland Clinic Journal of Medicine; 2009 (76 Supplement 4) S37-44

  24. ACC/AHA Updated 2007 Guidelines:Perioperative Care for Noncardiac Surgery • BARE METAL STENT • WAIT 6 weeks (3 months) for non-urgent, elective surgery • URGENT surgery within first 6 weeks requires dual antiplatelet therapy • DRUG-ELUTING STENT • WAIT one year for non-urgent, elective surgery • URGENT surgery within 6 months requires dual antiplatelet therapy • URGENT surgery after 6 months must continue aspirin (81 mg/day), restart the clopidogrel after 5 days with 300 mg loading dose

  25. Question 13. • Answer : C; Surgical valve replacement Aortic Stenosis: Who should undergo surgery, transcatheter valve replacement? Cleveland Clinic Journal of Medicine Volume 79, No. 7, July 2012 (487-497)

  26. Severe aortic stenosis with symptoms requires surgery

  27. Question 14. • Answer: B; IV sodium nitroprusside

  28. Acute, severe mitral regurgitation is a surgical problem Etiologies of acute MR • Acute MI (papillary dysfunction) • Post-MI (papillary necrosis) • Ruptured chord (chronic MVP) • Infectious Endocarditis Pathophysiology Left ventricle unloads favorably toward path with lowest resisistance: aorta-forward left atrium-backward Management LOWER the systemic blood pressure to favor forward flow: sodium nitroprusside DIURESE TO reduce pulmonary edema SURGERY to REPLACE the VALVE

  29. Question 15. • Answer: C; Follow up ultrasound in 6 to 12 months

  30. Manage asymptomatic abdominal aortic aneurysm found on routine screening Who gets screened for AAA? What to do with the results? NO REPEAT SCREEN No aneurysm REPEAT SCREEN IN 6-12 MONTHS Aneurysm 3-5.5 cm diameter REPAIR: >5.5 cm on presentation Rapidly expanding with surveillance imaging (5 mm in 6 months or 10 mm in one year) Coexisting PAD or peripheral artery aneurysm • USPSTF: • Men 65-75 who have ever smoked one time U/S • No screening in women  • ACC/AHA 2005: • Men 60 or older with family hx of AAA in parent or sibling • Men 65-75 who have ever smoked • Medicare coverage: • Men 65-75 who have smoked at least 100 cigarettes in their lifetime • Males or females with family hx of AAA

  31. Question 16. • Answer: D; Intravenous B-blockade followed by IV sodium nitroprusside

  32. Anatomy of the Aorta

  33. Treat a descending aortic intramural hematoma in a lesion of the descending aorta (type B)

  34. Aortic Dissection versus Aortic Intramural Hematoma Dissection Intramural hematoma • Entrance tear and exit tear from the intima forming a channel inside the media of the aorta with a flap • More commonly type A (Ascending and Arch) • Better prognosis with surgical treatment • Rupture of vasovasorum feeding the aortic media to create a hematoma within the medial layer with an intact intima • More commonly type B (Below LSCA) • Does better with medical treatment • B-blocker + sodium nitroprusside

  35. Question 17. • Answer: C; IV amiodarone

  36. Manage a patient with a hemodynamically stable wide-complex tachycardia Differential Diagnosis of Monomorphic Wide Complex Tachycardia: • Ventricular Tachycardia (especially if known CAD or cardiomyopathy) • Supraventricular Tachycardia with aberrency • AntidromicAtrioventricular Reciprocating Tachycardia(Pre-excitiation) VT Pearls: • Stable hemodynamics does NOT rule OUT VT • AV dissociation confirms the diagnosis of VT • Cannon A Waves • Variable S1 indicate atrium contracting against a closed tricuspid valve • Treatment of choice should be amiodarone, procainamide, or sotalol

  37. Question 18. • Answer: D; Haloperidol

  38. Manage the risk for torsades de pointes in the hospital setting Risk factors for Torsades de Pointes: • QTc interval > 500 msec or increase by 60 msec or more after initiation of a QTc prolonging medication • Older age • Female sex • Multiple QTc prolonging medications 5. Hypokalemia and hypomagnesemia TREATMENT: Stop the offending medication! www.qtdrugs.org

  39. Question 19. • Answer: C; Three sets of blood cultures

  40. Understand the manifestations of infective endocarditis

  41. MAJOR CRITERIA FOR IE: BLOOD CULTURES: • Typical microorganism for IE from 2 separate blood cultures • Persistently positive blood cultures drawn 12 hours apart, or 3 separate cultures drawn at least 1 hour apart • Single positive culture for coxiellaburnetii, or Ig G titer > 1:800 ENDOCARDIAL INVOLVEMENT: • Positive echocardiographic evidence of IE • New valvular regurgitation

  42. Question 20. • Answer: B; Constrictive pericarditis

  43. Diagnose irradiation-induced constrictive pericarditis Etiologies: • Idiopathic or viral (42-49%) • Post-cardiac surgery (11-37%) • Post-radiation therapy (9-31%) Hodgkins/Breast • Connective Tissue Disease (3-7%) • Post-Infectious (3-6%) TB or purulent • Other (1-10%) Patient symptoms: • Heart failure (67%) • Chest pain (8%) • Abdominal symptoms (7%) • Tamponade (5%) Physical Exam: • Elevated JVP with rapid x and y descent • Kussmal’s sign • Pericardial knock before S3 • Cachexia, edema

More Related